Dissociated thyromimetic effects of 3, 5, 3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels1

P. Beck-Peccoz, A. Sartorio, C. De Medici, G. Grugni, F. Morabito, G. Faglia

Research output: Contribution to journalArticle

Abstract

Although TRIAC is bound at least twice as avidly to nuclear receptor as T3, its thyromimetic potency is relatively low and its effect at the pituitary level on thyrotropin (TSH) secretion seems to be dissociated from that at the peripheral tissue level. In order to gain further insight into the complex effects of this thyroid hormone analog, we studied the effects of long-term TRIAC administration (2.8 mg/day for 2 months) on TSH secretion, circulating free thyroid hormone (FT4 and FT3) levels and some parameters able to evaluate the peripheral thyroid hormone action, in 5 mild obese subjects on low caloric diet (1200 kcal /day). The results were compared to those obtained in 5 mild obese subjects matched for age, sex and weight on low caloric diet alone. TRIAC administration completely inhibited the secretion of both basal and TRH-stimulated TSH in few days, and consequently serum FT4 and FT3 concentrations progressively dropped to very low levels, while no significant changes in both TSH and free thyroid hormone levels were recorded in the control group. The body weight significahtly fell in both groups, without any difference between TRIAC treated and untreated patients. The heart rate was constant throughout the course of the study in both groups of patients. Serum total cholesterol, triglyceride and total lipid concentrations significantly decreased in both groups, and the decrement recorded in TRIAC treated patients was not significantly different from that found in patients on diet alone. The low serum levels of sex hormone-binding globulin (SHBG) completely normalized in both groups (TRIAC + diet: from 19.9 ± 7.4 to 49.0 ± 14.5 nmol /l, p <0.01; diet alone: from 29.0 ± 6.0 to 50.6 ± 5.2 nmol/l, p <0.01), without any difference between TRIAC treated and untreated patients. The present data confirm the previously reported discrepancy between the strong in vitro nuclear binding of TRIAC and its poor thyromimetic activity in vivo, and demonstrate that TRIAC at the dose which completely suppresses TSH secretion does not cause any particular metabolic effect at the peripheral tissue level.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalJournal of Endocrinological Investigation
Volume11
Issue number2
DOIs
Publication statusPublished - 1988

Fingerprint

Thyroid Hormones
Diet
Serum
3,3',5-triiodothyroacetic acid
Sex Hormone-Binding Globulin
Thyrotropin
Cytoplasmic and Nuclear Receptors
Triglycerides
Heart Rate
Cholesterol
Body Weight
Lipids
Weights and Measures
Control Groups

Keywords

  • SHBG
  • Thyroid hormone analogs
  • TRIAC
  • TSH secretion

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Dissociated thyromimetic effects of 3, 5, 3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels1. / Beck-Peccoz, P.; Sartorio, A.; De Medici, C.; Grugni, G.; Morabito, F.; Faglia, G.

In: Journal of Endocrinological Investigation, Vol. 11, No. 2, 1988, p. 113-118.

Research output: Contribution to journalArticle

@article{31ec459f37fa4988bf38d9ae2e8a0232,
title = "Dissociated thyromimetic effects of 3, 5, 3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels1",
abstract = "Although TRIAC is bound at least twice as avidly to nuclear receptor as T3, its thyromimetic potency is relatively low and its effect at the pituitary level on thyrotropin (TSH) secretion seems to be dissociated from that at the peripheral tissue level. In order to gain further insight into the complex effects of this thyroid hormone analog, we studied the effects of long-term TRIAC administration (2.8 mg/day for 2 months) on TSH secretion, circulating free thyroid hormone (FT4 and FT3) levels and some parameters able to evaluate the peripheral thyroid hormone action, in 5 mild obese subjects on low caloric diet (1200 kcal /day). The results were compared to those obtained in 5 mild obese subjects matched for age, sex and weight on low caloric diet alone. TRIAC administration completely inhibited the secretion of both basal and TRH-stimulated TSH in few days, and consequently serum FT4 and FT3 concentrations progressively dropped to very low levels, while no significant changes in both TSH and free thyroid hormone levels were recorded in the control group. The body weight significahtly fell in both groups, without any difference between TRIAC treated and untreated patients. The heart rate was constant throughout the course of the study in both groups of patients. Serum total cholesterol, triglyceride and total lipid concentrations significantly decreased in both groups, and the decrement recorded in TRIAC treated patients was not significantly different from that found in patients on diet alone. The low serum levels of sex hormone-binding globulin (SHBG) completely normalized in both groups (TRIAC + diet: from 19.9 ± 7.4 to 49.0 ± 14.5 nmol /l, p <0.01; diet alone: from 29.0 ± 6.0 to 50.6 ± 5.2 nmol/l, p <0.01), without any difference between TRIAC treated and untreated patients. The present data confirm the previously reported discrepancy between the strong in vitro nuclear binding of TRIAC and its poor thyromimetic activity in vivo, and demonstrate that TRIAC at the dose which completely suppresses TSH secretion does not cause any particular metabolic effect at the peripheral tissue level.",
keywords = "SHBG, Thyroid hormone analogs, TRIAC, TSH secretion",
author = "P. Beck-Peccoz and A. Sartorio and {De Medici}, C. and G. Grugni and F. Morabito and G. Faglia",
year = "1988",
doi = "10.1007/BF03350116",
language = "English",
volume = "11",
pages = "113--118",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "2",

}

TY - JOUR

T1 - Dissociated thyromimetic effects of 3, 5, 3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels1

AU - Beck-Peccoz, P.

AU - Sartorio, A.

AU - De Medici, C.

AU - Grugni, G.

AU - Morabito, F.

AU - Faglia, G.

PY - 1988

Y1 - 1988

N2 - Although TRIAC is bound at least twice as avidly to nuclear receptor as T3, its thyromimetic potency is relatively low and its effect at the pituitary level on thyrotropin (TSH) secretion seems to be dissociated from that at the peripheral tissue level. In order to gain further insight into the complex effects of this thyroid hormone analog, we studied the effects of long-term TRIAC administration (2.8 mg/day for 2 months) on TSH secretion, circulating free thyroid hormone (FT4 and FT3) levels and some parameters able to evaluate the peripheral thyroid hormone action, in 5 mild obese subjects on low caloric diet (1200 kcal /day). The results were compared to those obtained in 5 mild obese subjects matched for age, sex and weight on low caloric diet alone. TRIAC administration completely inhibited the secretion of both basal and TRH-stimulated TSH in few days, and consequently serum FT4 and FT3 concentrations progressively dropped to very low levels, while no significant changes in both TSH and free thyroid hormone levels were recorded in the control group. The body weight significahtly fell in both groups, without any difference between TRIAC treated and untreated patients. The heart rate was constant throughout the course of the study in both groups of patients. Serum total cholesterol, triglyceride and total lipid concentrations significantly decreased in both groups, and the decrement recorded in TRIAC treated patients was not significantly different from that found in patients on diet alone. The low serum levels of sex hormone-binding globulin (SHBG) completely normalized in both groups (TRIAC + diet: from 19.9 ± 7.4 to 49.0 ± 14.5 nmol /l, p <0.01; diet alone: from 29.0 ± 6.0 to 50.6 ± 5.2 nmol/l, p <0.01), without any difference between TRIAC treated and untreated patients. The present data confirm the previously reported discrepancy between the strong in vitro nuclear binding of TRIAC and its poor thyromimetic activity in vivo, and demonstrate that TRIAC at the dose which completely suppresses TSH secretion does not cause any particular metabolic effect at the peripheral tissue level.

AB - Although TRIAC is bound at least twice as avidly to nuclear receptor as T3, its thyromimetic potency is relatively low and its effect at the pituitary level on thyrotropin (TSH) secretion seems to be dissociated from that at the peripheral tissue level. In order to gain further insight into the complex effects of this thyroid hormone analog, we studied the effects of long-term TRIAC administration (2.8 mg/day for 2 months) on TSH secretion, circulating free thyroid hormone (FT4 and FT3) levels and some parameters able to evaluate the peripheral thyroid hormone action, in 5 mild obese subjects on low caloric diet (1200 kcal /day). The results were compared to those obtained in 5 mild obese subjects matched for age, sex and weight on low caloric diet alone. TRIAC administration completely inhibited the secretion of both basal and TRH-stimulated TSH in few days, and consequently serum FT4 and FT3 concentrations progressively dropped to very low levels, while no significant changes in both TSH and free thyroid hormone levels were recorded in the control group. The body weight significahtly fell in both groups, without any difference between TRIAC treated and untreated patients. The heart rate was constant throughout the course of the study in both groups of patients. Serum total cholesterol, triglyceride and total lipid concentrations significantly decreased in both groups, and the decrement recorded in TRIAC treated patients was not significantly different from that found in patients on diet alone. The low serum levels of sex hormone-binding globulin (SHBG) completely normalized in both groups (TRIAC + diet: from 19.9 ± 7.4 to 49.0 ± 14.5 nmol /l, p <0.01; diet alone: from 29.0 ± 6.0 to 50.6 ± 5.2 nmol/l, p <0.01), without any difference between TRIAC treated and untreated patients. The present data confirm the previously reported discrepancy between the strong in vitro nuclear binding of TRIAC and its poor thyromimetic activity in vivo, and demonstrate that TRIAC at the dose which completely suppresses TSH secretion does not cause any particular metabolic effect at the peripheral tissue level.

KW - SHBG

KW - Thyroid hormone analogs

KW - TRIAC

KW - TSH secretion

UR - http://www.scopus.com/inward/record.url?scp=0023915739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023915739&partnerID=8YFLogxK

U2 - 10.1007/BF03350116

DO - 10.1007/BF03350116

M3 - Article

C2 - 3361080

AN - SCOPUS:0023915739

VL - 11

SP - 113

EP - 118

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 2

ER -